ProPhase Labs, Inc. (NASDAQ:PRPH) Short Interest Update

ProPhase Labs, Inc. (NASDAQ:PRPH) saw a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 116,400 shares, an increase of 19.1% from the December 31st total of 97,700 shares. Based on an average daily volume of 290,200 shares, the short-interest ratio is presently 0.4 days.

ProPhase Labs Trading Up 1.4 %

PRPH traded up $0.00 during midday trading on Monday, hitting $0.27. 15,034,780 shares of the company were exchanged, compared to its average volume of 1,119,311. The firm has a market capitalization of $6.37 million, a P/E ratio of -0.21 and a beta of -0.36. The firm’s 50 day moving average price is $0.65 and its 200-day moving average price is $1.73. The company has a quick ratio of 1.33, a current ratio of 1.47 and a debt-to-equity ratio of 0.48. ProPhase Labs has a 1-year low of $0.22 and a 1-year high of $7.48.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on shares of ProPhase Labs in a report on Saturday. They set a “sell” rating on the stock.

Institutional Trading of ProPhase Labs

Several institutional investors have recently added to or reduced their stakes in the stock. Sheets Smith Wealth Management acquired a new position in shares of ProPhase Labs in the 4th quarter worth approximately $158,000. Geode Capital Management LLC lifted its holdings in ProPhase Labs by 9.2% in the third quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock valued at $389,000 after buying an additional 13,590 shares during the period. Finally, HighTower Advisors LLC boosted its position in ProPhase Labs by 18.3% during the third quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock valued at $434,000 after acquiring an additional 27,673 shares during the last quarter. 9.45% of the stock is currently owned by institutional investors.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.